Trial Profile
A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced, Non CCR5-Tropic HIV-1 Infected Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Expanded access; Therapeutic Use
- Sponsors Pfizer
- 22 Jul 2011 Actual end date changed from Sep 2012 to Jul 2011 as reported by ClinicalTrials.gov (Extension trial; NCT00801515).
- 22 Jul 2011 Actual end date changed from Sep 2012 to Jul 2011 as reported by ClinicalTrials.gov (Extension trial; NCT00801515).
- 07 Jul 2009 Trial phase changed from II/III to III as reported by ClinicalTrials.gov (NCT00801515)